QPS Acquires JSW Life Sciences

QPS, LLC has acquired majority interest in JSW Life Sciences GmbH, a provider of preclinical and Phase II–IV drug development services. The unit will be renamed QPS JSW.
 
JSW is a full service CRO and specializes in CNS diseases including Alzheimer’s, Parkinson’s, Huntington’s, stroke, depression, psychosis and schizophrenia. JSW also has capabilities in preclinical efficacy studies including in vitro molecular and cellular analysis, as well as experience and access to unique biomarker technologies, including an exclusive license to the A4-assay for A-beta oligomers from Amorfix. JSW’s clinical operations focus on clinical development from Phase II – IV trials, including project planning, project management, trial monitoring, database management, data analysis, medical writing and regulatory affairs.
 
“This strategic expansion in our preclinical service offerings and Phase II-IV clinical capability represents our fifth cross-border acquisition, thereby pushing QPS further up as a high-quality contract research provider in the ranks of the global CRO business space,” said Ben Chien, chief executive officer of QPS. “Clients all over the world will now have access to an even wider range of the exceptional services they have come to expect from QPS, along with an expanding global footprint.”
 
Dr. Jaap Wieling, an industry veteran with a broad range of experience, and co-founder and managing director of QPS Netherlands, will lead QPS JSW. Dr. Jaap Wieling will work with Dr. Windisch and JSW’s existing staff.